Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
09/12/17
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
09/12/17CT ORDERCT ORDEROther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/24/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/22/17SC 13GA statement of beneficial ownership of common stock by certain personsOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/17/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/17/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
09/13/17Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons Join Together in a Program to Reduce Opioid Exposure for Patients Undergoing Wisdom Tooth Extraction
The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent PARSIPPANY, N.J., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced a collaboration with Aetna, one of the nation’s leading diversified health care benefits companies, with the support of the American Association of Oral and Maxillofacial Surgeons (AAOMS), on a national program aimed at reducing the number of opioid tablets prescribe... 
Printer Friendly Version
09/06/17Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations at the Upcoming New York School of Regional Anesthesia Annual Fall Symposium
Studies evaluate impact of EXPAREL administered as a regional nerve block for both upper and lower extremity surgeries PARSIPPANY, N.J., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that three poster presentations evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) administered as a regional nerve block to manage postsurgical pain will be presented at the New York School of Regional Anesthesia’s (NYSORA) 16th Annual Symp... 
Printer Friendly Version
09/05/17Pacira Pharmaceuticals to Present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference
PARSIPPANY, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference at 10:50 AM ET on Monday, September 11, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will ... 
Printer Friendly Version
08/31/17Pacira Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
PARSIPPANY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Wells Fargo Healthcare Conference at 8:15 AM ET on Thursday, September 7, 2017 in Boston, Massachusetts. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on t... 
Printer Friendly Version
08/09/17Pacira Pharmaceuticals to Present at the 2017 Wedbush Pacgrow Healthcare Conference
PARSIPPANY, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Wedbush Pacgrow Healthcare Conference at 9:10 AM ET on Tuesday, August 15, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Paci... 
Printer Friendly Version
08/02/17Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
-- EXPAREL® Net Product Sales Up 6% Year-Over-Year -- -- Full-year EXPAREL net product sales guidance of $290 to $310 million reiterated -- -- Conference Call Today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the second quarter ended June 30, 2017. “We are pleased to report another quarter of solid EXPAREL growth and remain on track to deliver our full-year financial gui... 
Printer Friendly Version
07/26/17Pacira Announces Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty
PILLAR study demonstrated a 78 percent decrease in opioid consumption and significantly better pain control with infiltration of EXPAREL plus bupivacaine versus bupivacaine alone Ten percent of patients in the EXPAREL arm required no opioids for pain control PARSIPPANY, N.J., July 26, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the publication of its Phase 4 PILLAR study of EXPAREL® (bupivacaine liposome injectable suspension) in total knee arthroplast... 
Printer Friendly Version
07/25/17Pacira Announces Topline Phase 3 Results for EXPAREL® as a Single-dose Nerve Block
Upper extremity study showed that EXPAREL significantly reduces pain scores and opioid use Lower extremity study defined safety and pharmacokinetic profile through 120 hours Timing for resubmission of supplemental New Drug Application remains on track Conference call scheduled for today at 8:30 AM ET PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the completion of two Phase 3 placebo-controlled studies evaluating the effica... 
Printer Friendly Version
07/25/17Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. The call can be accessed by dialin... 
Printer Friendly Version
06/15/17Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors
PARSIPPANY, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark I. Froimson, M.D. to its board of directors. Dr. Froimson is currently serving as the President of the American Association of Hip and Knee Surgeons (AAHKS). Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. “Mark’s deep cl... 
Printer Friendly Version
>> Access Older Press Releases

Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com


IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...